Abstract: The present invention provides a composition comprising an indirubin derivative for stimulating longitudinal bone growth. Because the composition for stimulating longitudinal bone growth according to the present invention is shown to be effective in longitudinal bone growth, it may be used not only as a composition for stimulating longitudinal bone growth, but also as a pharmaceutical composition for treating or preventing short stature, microplasia, dwarfism, or precocious puberty.

Abstract: The present invention provides a composition comprising an indirubin derivative for stimulating longitudinal bone growth. Because the composition for stimulating longitudinal bone growth according to the present invention is shown to be effective in longitudinal bone growth, it may be used not only as a composition for stimulating longitudinal bone growth, but also as a pharmaceutical composition for treating or preventing short stature, microplasia, dwarfism, or precocious puberty.

Abstract: The present disclosure relates to a composition for promoting wound healing that may be used as a pharmaceutical composition, or a cosmetic composition for promoting wound healing, which contains a polypeptide including an amino acid sequence of SEQ ID NO 1. The composition may be usefully used for a wound care drug or a functional cosmetic product for wound care.

Abstract: The present invention provides a composition comprising an indirubin derivative for stimulating longitudinal bone growth. Because the composition for stimulating longitudinal bone growth according to the present invention is shown to be effective in longitudinal bone growth, it may be used not only as a composition for stimulating longitudinal bone growth, but also as a pharmaceutical composition for treating or preventing short stature, microplasia, dwarfism, or precocious puberty.

Abstract: There are provided Idbf (inhibitor of Dvl and bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/?-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/?-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/?-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/?-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/?-catenin signaling pathway.

Abstract: The present disclosure relates to a composition for promoting wound healing that may be used as a pharmaceutical composition, or a cosmetic composition for promoting wound healing, which contains a polypeptide including an amino acid sequence of SEQ ID NO 1. The composition may be usefully used for a wound care drug or a functional cosmetic product for wound care.

Abstract: There are provided Idbf (inhibitor of Dvl and Bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/?-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/?-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/?-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/?-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/?-catenin signaling pathway.